Promising Results for New Antibody Drug in Non-Small Cell Lung Cancer Patients
Today is the final day of the European Cancer Conference in Amsterdam. The organisers have released a stream of press releases to coincide with the conference, which you can browse here:
However I just wanted to pick out one, which describes recent results with one of a new group of antibody treatments that block the interaction between PD-L1 and PD-1.
As they explain in the press release:
“The programmed death 1 protein PD-1 and its signalling molecule (or ligand) PD-L1 prevent the body’s immune system from attacking and killing cancer cells and this allows the cancer to spread.
However, the anti-PD-L1 monoclonal antibody, MPDL3280A, works by blocking the interaction between PD-L1 and the immune system, thereby boosting a patient’s anti-cancer immune response.
The same news is covered on Medscape:
One of the most exciting aspects of the news is the discovery that benefits smokers and ex-smokers – people who are highly unlikely to have cancers that will respond to EGF-R inhibitors (Iressa & Tarceva) or ALK inhibitors (Zalkori).